modRNA Therapeutics Versus hiPSC-Derived Cell and Cell Products for Myocardial Repair: Remuscularization of Injured Ventricle in Large Mammals
Clinical physicians, physician-scientists, basic scientists, other healthcare professionals, and trainees require regular updates on mechanisms, novel therapeutics, and medical and surgical technologies to manage cardiovascular diseases and on cardiovascular basic, translational, and clinical science. The series aims to expand the knowledge of learners specifically with regard to the pathophysiology and physiology of cardiovascular disease, the mechanisms of cardiovascular science and clinical studies, the analysis and interpretation of results, and the integration of findings into science and clinical practice. A focus of the series will be to discuss the basic science underlying cardiovascular clinical studies and professional guidelines and thereby promote a wider dissemination of this information to achieve evidence-based patient care.
Physicians, fellows, residents, and other healthcare providers.
At the conclusion of the session, the participants should be able to:
Describe novel applications of mRNA-based therapeutics.
Review how cell and cell products could become treatment options for cardiovascular disease in the future.
Discuss the major roadblocks in cardiac cell therapy and the potential approaches to overcome these problems.
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation